Xiagem DS 2 Tablet PR contains a combination of Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination provides complementary mechanisms of action, improving glycemic control in patients inadequately controlled by diet and exercise alone. Xiagem DS 2 Tablet PR is prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. It is particularly useful for patients who require dual therapy to achieve target glycemic levels. The prolonged-release formulation allows for once-daily dosing, promoting better patient adherence. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributable to metformin, while hypoglycemia risk is associated with glimepiride. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This combination therapy should be used under medical supervision to optimize efficacy and minimize potential risks.